This anti-metastatic profile is concordant with the expected consequences of disrupting MMP12-driven ECM turnover and survival signaling and with prior links between MMP12, EMT, and the uPA/uPAR/TGF-β/AKT axis in NSCLC [20,25,49]. Here, PLAU is linked to non-small cell lung carcinoma.